Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma

Autor: Chantal Mengus, Antonio Juretić, Zeljko Kastelan, Giulio C. Spagnoli, Nikolina Basic-Jukic, Malte Rieken, Ivana Ilić, Tvrtko Hudolin, Katarina Levarda-Hudolin
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Male
Cytoplasm
Pathology
medicine.medical_specialty
endocrine system
Lymphoma
B-Cell
medicine.drug_class
medicine.medical_treatment
Biology
Monoclonal antibody
General Biochemistry
Genetics and Molecular Biology
Testicular Neoplasms
Antigen
Antigens
Neoplasm
hemic and lymphatic diseases
Testis
medicine
NY-ESO-1
Humans
primary testicular lymphoma
DLBCL
cancer/testis antigens
MAGE-A
immunotherapy
neoplasms
B cell
Medicine(all)
Biochemistry
Genetics and Molecular Biology(all)
Research
Gene Expression Profiling
Antibodies
Monoclonal
Membrane Proteins
General Medicine
Immunotherapy
medicine.disease
Immunohistochemistry
Lymphoma
Gene Expression Regulation
Neoplastic
medicine.anatomical_structure
Testicular Lymphoma
Cancer/testis antigens
Lymphoma
Large B-Cell
Diffuse
Primary testicular lymphoma
Melanoma-Specific Antigens
Zdroj: Journal of Translational Medicine
DOI: 10.1186/1479-5876-11-123
Popis: BACKGROUND: Primary testicular lymphoma (PTL) is a rare and lethal disease. The most common histological subtype is diffuse large B-cell lymphoma (DLBCL). Standard treatments are frequently ineffective. Thus, the development of novel forms of therapy is urgently required. Specific immunotherapy generating immune responses directed against antigen predominantly expressed by cancer cells such as cancer-testis antigens (CTA) may provide a valid alternative treatment for patients bearing PTL, alone or in combination with current therapies. ----- METHODS: Three monoclonal antibodies (mAbs), 77B recognizing MAGE-A1, 57B recognizing an epitope shared by multiple MAGE-A CTA (multi-MAGE-A specific) and D8.38 recognizing NY-ESO-1/LAGE-1 were used for immunohistochemical staining of 27 PTL, including 24 DLBCL. ----- RESULTS: Expression of MAGE-A1 was infrequently detectable in DLBCL specimens (12.50%), whereas multi-MAGE-A and NY-ESO-1/LAGE-1 specific reagents stained the cytoplasms of tumor cells in DLBCL specimens with higher frequencies (54.17% and 37.50%, respectively) with different expression levels. ----- CONCLUSIONS: These results suggest that MAGE-A and NY-ESO-1/LAGE-1, possibly in combination with other CTA, might be used as targets for specific immunotherapy in DLBCL.
Databáze: OpenAIRE
Externí odkaz: